Neuronetics (NASDAQ:STIM – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01), MarketWatch Earnings reports. Neuronetics had a negative net margin of 56.39% and a negative return on equity of 33.24%. During the same period in the prior year, the firm earned ($0.31) earnings per share. Neuronetics updated its FY 2022 guidance to EPS and its Q2 2022 guidance to EPS.
Shares of Neuronetics stock traded up $0.31 during trading on Friday, reaching $2.57. 487,389 shares of the stock traded hands, compared to its average volume of 258,965. The company has a market capitalization of $68.43 million, a price-to-earnings ratio of -2.13 and a beta of 2.31. The business has a fifty day simple moving average of $2.92 and a two-hundred day simple moving average of $3.65. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.34 and a quick ratio of 6.93. Neuronetics has a 52-week low of $1.98 and a 52-week high of $17.92.
In related news, major shareholder Cannell Capital Llc purchased 106,455 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The stock was bought at an average price of $2.13 per share, for a total transaction of $226,749.15. Following the completion of the transaction, the insider now owns 3,329,150 shares in the company, valued at approximately $7,091,089.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Furlong sold 10,029 shares of Neuronetics stock in a transaction dated Wednesday, March 9th. The stock was sold at an average price of $3.00, for a total value of $30,087.00. The disclosure for this sale can be found here. In the last 90 days, insiders have bought 296,413 shares of company stock valued at $764,319. Company insiders own 5.20% of the company’s stock.
Separately, Zacks Investment Research cut Neuronetics from a “buy” rating to a “hold” rating in a report on Saturday, March 12th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $10.06.
About Neuronetics (Get Rating)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
- Get a free copy of the StockNews.com research report on Neuronetics (STIM)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.